Regentis Biomaterials reported a net loss of $2.6 million, or $0.44 per share, for the six months ended June 30, 2026, compared to a $3.2 million loss in the prior year period. The company completed a private placement in June 2026 raising approximately $6.5 million and held cash reserves of $9.0 million as of June 30, 2026. Clinical progress includes treating 43 of 80 patients in its U.S. pivotal GelrinC trial, with enrollment completion expected by year-end 2026. The company also received regulatory approval for a new manufacturing process that increases production yield by 400% and expanded its European commercialization network. Regentis Biomaterials Ltd is a regenerative medicine company focused on developing innovative tissue repair solutions using hydrogel implants.

Regentis Biomaterials Ltd. announced that the Japan Patent Office has issued a Notice of Allowance for its proprietary organic solvent-free manufacturing process and liquid formulation used in GelrinC, its regenerative treatment for articular cartilage injuries. This technology provides a 5x increase in yield and improved process efficiency. The company is currently advancing commercialization in Europe and conducting a pivotal U.S. FDA study with over 50% enrollment. Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions.

On July 15, 2026, Regentis Biomaterials Ltd. announced it received European regulatory approval for a new GelrinC manufacturing process. This process increases production yield by 400% and supports the company's upcoming European commercial launch. The company operates in the biomaterials industry and develops medical-grade materials.

On July 9, 2026, Regentis Biomaterials Ltd. announced that shareholders approved all fourteen proposals presented at the Adjourned Annual General Meeting of Shareholders. The proposals were previously detailed in the Company’s Notice and Proxy Statement dated May 28, 2026, and its subsequent amendment from June 4, 2026. Regentis Biomaterials Ltd. is a biotechnology company focused on developing biomaterials for medical applications.

Regentis Biomaterials Ltd. adjourned its Annual General Meeting of Shareholders, originally scheduled for July 2, 2026, due to a lack of quorum. The meeting is reconvened for July 9, 2026, at 3:00 p.m. Israel time at the offices of Amit, Pollak, Matalon & Co. in Tel Aviv. The company develops biomaterials for medical applications.

Regentis Biomaterials Ltd. entered into definitive securities purchase agreements on June 17, 2026, to issue and sell 1,844,543 ordinary shares and pre-funded warrants to accredited and institutional investors. The offering includes ordinary warrants to purchase up to 1,857,143 shares at a combined price of $3.50 per share and warrant, or $3.4999 for pre-funded warrants. Expected gross proceeds are approximately $6.5 million, with the offering anticipated to close around June 23, 2026. Net proceeds will fund the GelrinC clinical trial, FDA pre-market approval preparations, Gelrin technology platform optimization, manufacturing scale-up, and European market entry. ThinkEquity LLC is serving as the exclusive placement agent. Regentis Biomaterials Ltd. is a biotechnology company developing biomaterial technologies.